StreetAlpha.app
Home › Stocks › LQDA

Liquidia Corp (LQDA)

Healthcare
$54.43
▼ −3.88%
LAST CLOSE · NOV 20

Liquidia is a biopharmaceutical company that sells YUTREPIA, an inhaled treprostinil treatment for pulmonary arterial hypertension. It last closed at $54.43 on Nov 20, down 3.88% on the day. The next earnings report for LQDA is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, LQDA reported EPS of -$2.64 on revenue of $225.3M, with revenue up 314.6% from a year ago. Over its last 8 reports the stock moved an average of 7.9% the session after earnings. Over the last 12 months LQDA insiders bought $318K of stock on the open market and sold $226.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is LQDA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LQDA.

Key Stats

Last 12 months
Results
Revenue
$621.9M
+798.4% vs a year ago
Net income
−$94.2M
−15.1% margin
EPS (diluted)
−$1.05
Free cash flow
$291.2M
46.8% margin
Valuation
Market cap
$4.9B
90.1M shares
P/E
–
No P/E while losing money
Price to sales
7.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$396.1M
At Sep 30
Shareholder equity
−$25.4M
Shares outstanding
90.1M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $12.9M$12.9MFY2021FY2022: $15.9M$15.9MFY2022FY2023: $17.5M$17.5MFY2023FY2024: $14.0M$14.0MFY2024FY2025: $158.3M$158.3MFY2025

From LQDA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
-$2.64
Quarter ended Sep 2026
Year ago EPS
-$0.04
Same quarter last year
Revenue
$225.3M
+314.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.46Dec '24Mar 2025: -$0.45Mar '25Jun 2025: -$0.49Jun '25Sep 2025: -$0.04Sep '25Dec 2025: $0.17Dec '25Mar 2026: $0.52Mar '26Jun 2026: $0.74Jun '26Sep 2026: -$2.64Sep '26Latest -$2.64
Revenue by quarter
Dec 2024: $2.9MDec '24Mar 2025: $3.1MMar '25Jun 2025: $8.8MJun '25Sep 2025: $54.3MSep '25Dec 2025: $92.0MDec '25Mar 2026: $132.9MMar '26Jun 2026: $171.7MJun '26Sep 2026: $225.3MSep '26Latest $225.3M
How LQDA moved after its last 8 reports
Average move the session after a report ±7.9%
Nov 10, 2026Time not announced+7.4%
Aug 12, 2026Time not announced−10.5%
May 11, 2026Time not announced+25.6%
Mar 5, 2026Time not announced+0.4%
Nov 3, 2025Time not announced+3.5%
Aug 12, 2025Time not announced+13.7%
May 8, 2025Time not announced−1.2%
Mar 19, 2025Time not announced+1.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LQDAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LQDA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LQDA

Technical Analysis

LQDA · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 9% above its 20 day and 12% above its 50 day average. It is 1% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 59). The nearest support is the Pivot S1 at $53.20, and the nearest resistance the 200 day average at $55.02.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 6.6%/day
Key levels
$93.6152 week high+72.0%
$62.72100 day average+15.2%
$59.50Swing high (Nov 13)+9.3%
$56.44Pivot R1+3.7%
$55.20Pivot+1.4%
$55.02200 day average+1.1%
$54.43Last close
$53.20Pivot S1−2.3%
$53.06Swing low (Jun 3)−2.5%
$49.7920 day average−8.5%
$47.7750 day average−12.2%
$22.3152 week low−59.0%
Indicators
RSI (14)59.40Middle of its rangeNeutral
MACD3.31Above its signal lineBullish
Stochastic79.5Middle of its rangeNeutral
ADX (14)32.5Trending up
Williams %R-28.2Oversold below −80, overbought above −20Neutral
CCI (20)68.3Oversold below −100, overbought above 100Neutral
Rate of change+22.6%Change over 10 sessionsBullish
ATR (14)$3.61Typical daily range, 6.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for LQDA

What happened before

See how LQDA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LQDA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LQDA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LQDAHow many large options trades hit LQDA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

LQDA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●180 buying vs 187 selling
  • ▲Held by funds +3.5 pts
  • ▼Funds holding -33
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call 1.57 to 1.62
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding307340−9.7%
In funds' top 10813−38.5%
Held by funds84.2%80.7%+3.5 pts
New / increased63 / 117127 / 103−21.7%
Reduced / sold out92 / 9582 / 34+61.2%
Put/call ratio1.621.57+3.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LQDA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LQDA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$318K1 buy · 1 insider
Sold$226.9M94 sales · 15 insiders
33% of the selling was under pre-arranged trading plans.
2025-12 sold $138K2026-01 sold $8.0M2026-03 sold $8.8M2026-04 sold $20.8M2026-05 bought $318K2026-05 sold $38.3M2026-06 sold $84.6M2026-07 sold $40.6M2026-08 sold $15.1M2026-09 sold $1.2M2026-10 sold $9.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 26Jason AdairChief Business OfficerSale plan688$43.19$30K
Oct 26Dana BoyleChief Accounting OfficerSale plan1,581$43.19$68K
Oct 12Jason AdairChief Business OfficerSale plan7,301$28.48$208K
Oct 12Dana BoyleChief Accounting OfficerSale plan5,892$28.48$168K
Oct 12Roger JeffsCEOSale plan32,744$28.48$933K
Oct 12Michael KasetaCFO and COOSale plan18,938$28.48$539K
Every insider buy and sale for LQDA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LQDA insider trades →

From SEC Form 4 filings by LQDA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LQDA is in one of them and how their past LQDA trades turned out.

LQDA in the AI portfolios
Loading…

LQDA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LQDA in an article yet. Here's the latest on the wider market.

LQDA in the news

About Liquidia

Liquidia is a biopharmaceutical company based in Morrisville, North Carolina, that develops and sells medicines for lung and blood vessel diseases. Its main product is YUTREPIA, an inhaled treprostinil powder used to treat pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. The company also shares profits from a generic treprostinil injection sold in the United States and is developing other treatments, including for pulmonary hypertension linked to COPD. Its customers include healthcare providers who treat these patients and the organizations that distribute and pay for these medicines.

Headquarters
Morrisville, NC